Protara Therapeutics, Inc. financial data

Symbol
TARA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, 3 Rd Floor, New York, NY
Fiscal year end
December 31
Former names
ArTara Therapeutics, Inc. (to 4/23/2020), PROTEON THERAPEUTICS INC (to 12/31/2019)
Latest financial report
10-K - Q4 2024 - Mar 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.32K % -1.22%
Debt-to-equity 11.5 % -14.4%
Return On Equity -44.7 % +10.1%
Return On Assets -40.1 % +8.58%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.8M shares +222%
Common Stock, Shares, Outstanding 35M shares +208%
Entity Public Float 35M USD +94.4%
Common Stock, Value, Issued 35K USD +218%
Weighted Average Number of Shares Outstanding, Basic 20.6M shares +81.7%
Weighted Average Number of Shares Outstanding, Diluted 20.6M shares +81.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 31.7M USD +26.9%
General and Administrative Expense 17.5M USD -6.3%
Operating Income (Loss) -49.2M USD -12.7%
Nonoperating Income (Expense) 4.56M USD +42.8%
Net Income (Loss) Attributable to Parent -44.6M USD -10.3%
Earnings Per Share, Basic -2.17 USD/shares +39.2%
Earnings Per Share, Diluted -2.17 USD/shares +39.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 163M USD +311%
Marketable Securities, Current 7.49M USD -71.2%
Other Assets, Current 2K USD -94.6%
Assets, Current 172M USD +151%
Property, Plant and Equipment, Net 1.03M USD -20.8%
Operating Lease, Right-of-Use Asset 4.26M USD -19.2%
Other Assets, Noncurrent 27K USD +145%
Assets 181M USD +130%
Accounts Payable, Current 4.43M USD +82%
Employee-related Liabilities, Current 2.53M USD +19.9%
Accrued Liabilities, Current 5.41M USD +98%
Liabilities, Current 11M USD +78.3%
Operating Lease, Liability, Noncurrent 3.36M USD -25.1%
Liabilities 14.3M USD +34.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD
Retained Earnings (Accumulated Deficit) -245M USD -22.3%
Stockholders' Equity Attributable to Parent 167M USD +145%
Liabilities and Equity 181M USD +130%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD +19.5%
Net Cash Provided by (Used in) Financing Activities -76K USD -18.8%
Net Cash Provided by (Used in) Investing Activities 23.1M USD +134%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 35M shares +208%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 164M USD +306%
Deferred Tax Assets, Valuation Allowance 72.5M USD +37.6%
Deferred Tax Assets, Gross 74.3M USD +36.8%
Operating Lease, Liability 4.48M USD -18%
Depreciation 83K USD +7.79%
Payments to Acquire Property, Plant, and Equipment 6K USD -45.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -44.6M USD -12.1%
Lessee, Operating Lease, Liability, to be Paid 5.06M USD -20.8%
Property, Plant and Equipment, Gross 2.13M USD +0.61%
Operating Lease, Liability, Current 1.12M USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.43M USD +2.44%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD +5.12%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 575K USD -37.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 37.2M USD +21%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 718K USD -49.8%
Operating Lease, Payments 332K USD 0%
Additional Paid in Capital 412M USD +53.3%
Deferred Tax Assets, Net of Valuation Allowance 1.76K USD
Share-based Payment Arrangement, Expense 4.67M USD -23%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%